So how peripheral was Dipak Das’ resveratrol work, really?

In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”

Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?

Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges

Das, via UConn

Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.

First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges

A mega-correction, but no retraction, in the Journal of Cell Science

In our 2011 year-end post, we promised to keep

…an eye on what may be an emerging trend: The mega-correction. We’ve seen errata notices that correct so many different errors, it’s hard to believe the paper shouldn’t have been retracted. It’s unclear what this means yet, but watch this space for coverage of more examples.

We’ve found another example in the Journal of Cell Science, “Immunobiology of naïve and genetically modified HLA-class-I-knockdown human embryonic stem cells,” originally published in September 2011. The correction begins with what turns out to be a bit of an understatement: Continue reading A mega-correction, but no retraction, in the Journal of Cell Science

UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Das, via UConn

The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.

According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.

The university touted some of his early efforts in this field.

[Please also see our update posted Thursday.]

Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Eye of the needle? Paper about camels gets rejected, then published, then retracted

photo by http://www.flickr.com/photos/bysheribeari/ via Flickr

If there’s one thing worse than having your paper rejected by a journal, it’s having it retracted. But usually a paper has to be accepted before it’s published and withdrawn.

Not so for a study from the United Arab Emirates, “Detection and genotyping of GB virus-C in dromedary camels in the United Arab Emirates,” published in 2010 in Veterinary Microbiology.

The editors of the journal ruminated — hey now! is this thing on? — on the paper,  only to give it the thumbs down. But come to find out, it got published anyway. Thus, the following retraction notice, which appeared online last month: Continue reading Eye of the needle? Paper about camels gets rejected, then published, then retracted

How good are journals at policing authorship?

One of the most contentious issues in scholarly publishing is authorship. Sometimes there’s forgery involved, but most of the time the tension is more mundane but also more pernicious: Researchers who did most of the work wondering why “honorary” authors suddenly appear on papers, or wondering why their own names didn’t appear.

Journals, it would seem, are a good bulwark against such abuses. And many have subscribed to the International Committee of Medical Journal Editors’ (ICMJE) Uniform Requirements for Manuscripts, which include these requirements for authorship: Continue reading How good are journals at policing authorship?

Potti and colleagues retract 2008 JAMA paper

Anil Potti‘s retraction count is now eight with the withdrawal of a 2008 study in the Journal of the American Medical Association (JAMA).

Here’s the notice, which appeared online in JAMA sometime yesterday: Continue reading Potti and colleagues retract 2008 JAMA paper

Authors retract Journal of Cell Science study after realizing they were using the wrong gene constructs

What do you do when it turns out the materials you used in your successful experiment weren’t actually the materials you thought they were?

If you’re Peter Zammit, of King’s College London, and colleagues, you retract a 2008 paper in the Journal of Cell Science. Here’s the notice, for “B-catenin promotes self-renewal of skeletal-muscle satellite cells:” Continue reading Authors retract Journal of Cell Science study after realizing they were using the wrong gene constructs

JCO retracts article from major French cancer group over apparent plagiarism

David Khayat

The Journal of Clinical Oncology (JCO) has retracted a November 2011 editorial by a group of French cancer researchers, including David Khayat, the former head of that country’s National Cancer Institute, over what appears to be fairly extensive plagiarism.

Here’s the notice for the article, “Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored:” Continue reading JCO retracts article from major French cancer group over apparent plagiarism

Journal retracts heart stem cell paper (and pulls no punches) over image fraud

Some retractions beg for a kick of sand in the face, and others do the kicking. Here’s an example of what Charles Atlas might have written had he been a journal editor concerned with research integrity.

Experimental Biology and Medicine, the official journal of the Society for Experimental Biology and Medicine, has retracted a 2010 article by a group of stem cell scientists in China with an unfortunate affinity for a particular figure—one they’d used in a previous publication, only with a different description.

Here’s the notice for the paper, “Isolation and characterization of multipotent progenitor cells from the human fetal aorta wall,” which was cited five times before it was retracted, according to Thomson Scientific’s Web of Knowledge: Continue reading Journal retracts heart stem cell paper (and pulls no punches) over image fraud